Status:
COMPLETED
Efficacy and Safety Trial of the ALK HDM Tablet in House Dust Mite Allergic Subjects
Lead Sponsor:
ALK-Abelló A/S
Conditions:
Asthma
Eligibility:
All Genders
14+ years
Phase:
PHASE2
PHASE3
Brief Summary
The purpose of the trial is to determine if treatment of asthma patients allergic to house dust mites with the ALK HDM tablet can reduce the need of inhaled corticosteroids (ICS).
Eligibility Criteria
Inclusion
- A history of house dust mite induced asthma
- Use of inhaled corticosteroids (ICS)
- Positive skin prick test to house dust mites
- Positive specific IgE to house dust mites
Exclusion
- FEV1 lower than 70%
Key Trial Info
Start Date :
August 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
April 1 2008
Estimated Enrollment :
800 Patients enrolled
Trial Details
Trial ID
NCT00389363
Start Date
August 1 2006
End Date
April 1 2008
Last Update
August 17 2010
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Rigshospitalet
Copenhagen, Copenhagen, Denmark, 2100